Facial laser treatments—used for skin rejuvenation, scar revision, and pigmentary disorders—have become routine in dermatology and plastic surgery. However, despite technological improvements, complications remain frequent and sometimes serious. This paper asked a straightforward clinical question: what goes wrong with facial lasers, how often, and in whom? To answer this, the authors conducted a systematic review following rigorous PRISMA guidelines, searching three major medical databases (PubMed, Embase, Scopus) for peer-reviewed studies published between January 2019 and September 2025. They screened 2,435 records, included 13 studies reporting 2,010 cases, and stratified findings by laser type and patient skin phototype (Fitzpatrick classification I–VI).
The study found that post-inflammatory hyperpigmentation (PIH)—unwanted darkening of treated skin—was the most frequently reported complication overall, and dramatically more common in patients with Fitzpatrick IV–VI skin types (darker skin). Ablative lasers (CO₂ and Er:YAG, which vaporize skin layers) carried the highest risk of scarring and infection, while non-ablative fractional lasers were more likely to cause erythema and textural changes. Ocular (eye) injuries, though rare, were among the most severe complications. The authors cross-referenced their findings with FDA MAUDE adverse-event reports—real-world complaint databases—which corroborated their systematic findings and identified recurring safety patterns.
This review makes an important clinical contribution by synthesizing disparate evidence on laser safety and highlighting a critical disparity: darker-skinned patients face disproportionately higher rates of PIH and other pigmentary complications. However, significant limitations constrain the strength of conclusions. First, the included studies were highly heterogeneous—different laser types, treatment protocols, patient populations, and outcome definitions—making pooled quantitative analysis impossible and increasing risk of selection bias. Second, with only 13 studies included and 2,010 total cases, the evidence base is modest for deriving strong causal claims about individual device types. Third, the review relied heavily on published literature and MAUDE reports, both of which likely underestimate true complication rates due to publication bias and voluntary reporting bias. Fourth, the authors performed no formal meta-analysis and provided no statistical measures of uncertainty around their descriptive estimates.
From a longevity science perspective, this paper is tangentially related at best. Facial laser complications are important for patient safety and cosmetic outcomes, but they do not directly address mechanisms of aging, lifespan extension, or geroprotective interventions—the core domains of longevity research. The paper is a clinical safety review, not a study of aging biology or interventions that delay biological aging. Skin rejuvenation may be cosmetically important and even psychologically beneficial, but the cosmetic benefits of laser treatment have not been shown to extend healthspan or lifespan. The paper's value lies in clinical risk stratification and identifying gaps in standardized safety protocols, not in advancing fundamental understanding of aging or testing geroprotectors.
The authors appropriately conclude that complications remain clinically significant and call for consensus-driven best practices, standardized protocols, and personalized pre-treatment screening—reasonable clinical recommendations. However, the paper does not test any intervention or provide mechanistic insight into aging. It is a descriptive clinical safety review, not an intervention study or mechanistic investigation relevant to longevity research.
0 Comments
Log in to join the discussion.